Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.
People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...
Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...
A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...
- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a new study that analyzed cryopreserved CSF samples ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results